Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | NDAQ

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Atara Biotherapeutics, Inc. Pioneering off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.	United States of America	ATRA
Atea Pharmaceuticals, Inc. A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.	United States of America	AVIR
Athira Pharma, Inc. Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.	United States of America	ATHA
ATOSSA THERAPEUTICS, INC. Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.	United States of America	ATOS
ATUM CO., LTD. Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.	South Korea	355690
aTYR PHARMA INC Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.	United States of America	ATYR
Aura Biosciences, Inc. Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.	United States of America	AURA
Aurinia Pharmaceuticals Inc. Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.	United States of America	AUPH
AURORA CANNABIS INC A global producer and seller of medical and recreational cannabis and derivative products.	United States of America	ACB
Autolus Therapeutics plc Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.	United States of America	AUTL